...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Vote - please

Toinv, nice summary.

"In 2023 $1,587,506 was raised using promissory notes with warrants expiring in 2028. Is this a sign that interest is drying up?"

By my count, ~$11Mil CAN was raised in 2023.

 

Koo

Share
New Message
Please login to post a reply